Why the study?
Does doxorubicin inhibit natriuretic peptide gene expression in cultured neonatal rat atrial myocytes?
Does doxorubicin inhibit natriuretic peptide gene expression in cultured neonatal rat atrial myocytes?
Doxorubicin selectively inhibits BNP gene expression more potently than ANP in neonatal rat myocytes, suggesting BNP measurement may serve as a sensitive marker for early doxorubicin cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May support BNP as early marker of doxorubicin cardiotoxicity in rats; leaves open human validation before clinical use.
Doxorubicin is an antineoplastic agent with significant cardiotoxicity. We examined the effects of this agent on the expression of the natriuretic peptide (NP) genes in cultured neonatal rat atrial myocytes. Doxorubicin suppressed NP secretion, steady-state NP mRNA levels, and NP gene promoter activity. In each instance, brain NP (BNP) proved to be more sensitive than atrial NP (ANP) to the inhibitory effects of the drug. ICRF-187 and probucol reversed the inhibition by doxorubicin of ANP mRNA accumulation and ANP gene promoter activity while exerting no effect on BNP mRNA levels or promoter activity. This represents the first identification of the NP genes as targets of doxorubicin toxicity in the myocardial cell. This inhibition operates predominantly at a transcriptional locus and has more potent effects on BNP versus ANP secretion/gene expression. Measurement of BNP secretion/gene expression may provide a sensitive marker of early doxorubicin cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Chen et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: